Cargando...
Towards personalized therapy for patients with glioblastoma
Combined therapy with temozolomide and radiotherapy is a standard treatment and improves the survival for patients with newly diagnosed glioblastoma. However, the prognosis remains poor, with a median survival time of 12–15 months. Currently, several clinical trials of dose-dense temozolomide regime...
Gardado en:
| Publicado en: | Expert Rev Anticancer Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2011
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4297206/ https://ncbi.nlm.nih.gov/pubmed/22117160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/era.11.103 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|